“Preclinical development of IL-15-based immunocytokine SOT201 and antibody-drug conjugate SOT106 for treatment of solid tumors”

SOT201 is a novel cis-acting immunocytokine consisting of an antibody against PD-1 genetically fused to a sushi+ domain of IL-15Ra and IL-15 mutein. SOT201 targets PD-1⁺ TILs with a balanced cytokine potency to revive exhausted T cells in tumor microenvironment. SOT201 is currently being evaluated in Phase I clinical study VICTORIA-01 (NCT06163391) in metastatic advanced cancer patients.SOT106 is a novel antibody-drug conjugate (ADC) targeting LRRC15, comprised of a proprietary humanized monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a beta-glucuronidase (GUSB) cleavable linker. SOT106 anti-tumor efficacy was confirmed in soft tissue sarcoma and pediatric osteosarcoma models with moderate to low LRRC15 expression supporting its clinical development as a novel therapy for sarcomas. Combined with its superior performance over a clinical benchmark ADC, these results underscore the potential of SOT106 as a best-in-class targeted treatment for these challenging malignancies.